Discovery of Hydrazine Clubbed Thiazoles as Potential Antidiabetic Agents: Synthesis, Biological Evaluation, and Molecular Docking Studies
dc.authorid | Ciftci, Bilge/0000-0002-4153-1209 | |
dc.contributor.author | Kaya, Betul | |
dc.contributor.author | Tahtaci, Hakan | |
dc.contributor.author | Ciftci, Bilge | |
dc.contributor.author | Duran, Hatice Esra | |
dc.contributor.author | Necip, Adem | |
dc.contributor.author | Isik, Mesut | |
dc.contributor.author | Beydemir, Sukru | |
dc.date.accessioned | 2025-05-20T19:00:04Z | |
dc.date.issued | 2025 | |
dc.department | Bilecik Şeyh Edebali Üniversitesi | |
dc.description.abstract | In this study, hydrazine clubbed thiazole derivatives (3a-3j) were obtained by Hantzsch thiazole synthesis and characterized by MS, 1H NMR, and 13C NMR. The inhibitory potentials of the derivatives against diabetes-related enzymes such as aldose reductase (AR), alpha-glycosidase (alpha-GLY), and alpha-amylase (alpha-AMY) were experimentally determined, and the results were supported by molecular docking. The results showed that the derivatives (3a-3j) displayed varied degree of potential inhibitory activity, with KI values covering the following ranges: 5.47 +/- 0.53 to 23.89 +/- 1.46 nM for AR and 1.76 +/- 0.01 to 24.81 +/- 0.15 mu M for alpha-GLY, and with IC50 values 4.94-28.17 mu M for alpha-AMY, as compared to standard epalrestat and acarbose (KI: 34.53 +/- 2.52 nM for AR and 23.53 +/- 2.72 mu M for alpha-GLY, respectively). The selective activity of these derivatives on antidiabetic enzymes may be important for the treatment of diabetes and may lead to the development of alternative new compounds for this purpose. | |
dc.identifier.doi | 10.1002/ddr.70060 | |
dc.identifier.issn | 0272-4391 | |
dc.identifier.issn | 1098-2299 | |
dc.identifier.issue | 1 | |
dc.identifier.pmid | 39907170 | |
dc.identifier.scopus | 2-s2.0-85216990020 | |
dc.identifier.scopusquality | Q2 | |
dc.identifier.uri | https://doi.org/10.1002/ddr.70060 | |
dc.identifier.uri | https://hdl.handle.net/11552/8783 | |
dc.identifier.volume | 86 | |
dc.identifier.wos | WOS:001413129900001 | |
dc.identifier.wosquality | Q2 | |
dc.indekslendigikaynak | WoS | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.indekslendigikaynak | WoS - Science Citation Index Expanded | |
dc.language.iso | en | |
dc.publisher | Wiley | |
dc.relation.ispartof | Drug Development Research | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.snmz | KA_WOS_20250518 | |
dc.subject | ADME | |
dc.subject | aldose reductase | |
dc.subject | alpha-amylase | |
dc.subject | alpha-glucosidase | |
dc.subject | antidiabetic | |
dc.subject | molecular docking | |
dc.subject | thiazole | |
dc.title | Discovery of Hydrazine Clubbed Thiazoles as Potential Antidiabetic Agents: Synthesis, Biological Evaluation, and Molecular Docking Studies | |
dc.type | Article |